Neuroleptic drug effect on plasma dopamine-beta-hydroxylase in schizophrenia.
Plasma dopamine-beta-hydroxylase (DBH) activity was determined in 8 chronic schizophrenic patients following neuroleptic treatment for 2 months. Enzyme activity was decreased by 13.7 +/- 3.4% (mean +/- SD). The difference from pre-drug levels was not statistically significant. The reduction in DBH activity stabilized after the 1st month of treatment and was unrelated to neuroleptic drug load.
D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D002746:Chlorpromazine / Q000627:therapeutic use; D002908:Chronic Disease; D004299:Dopamine beta-Hydroxylase / Q000097:blood*; D005260:Female; D005476:Fluphenazine / Q000627:therapeutic use; D006220:Haloperidol / Q000627:therapeutic use; D006801:Humans; D008297:Male; D012559:Schizophrenia / Q000188:drug therapy / Q000201:enzymology*
D014150:Antipsychotic Agents; D004299:Dopamine beta-Hydroxylase; D006220:Haloperidol; D005476:Fluphenazine; D002746:Chlorpromazine